Indication for the treatment of PNE has been removed from all desmopressin nasal spray products at the request of the Medicines and Healthcare products Regulatory Agency
Compared with oral formulations of desmopressin, nasal forms have been associated with most of the serious adverse drug reactions reported in patients with PNE. Rare and serious adverse drug reactions reported have included hyponatraemia, water intoxication and convulsions.
Patients may complete their current course of treatment with desmopressin nasal spray but, at the next routine review, those requiring continued treatment should be prescribed an oral form of desmopressin.
All patients who start treatment with oral desmopressin should start at the lowest recommended dose, regardless of the dose of spray they have been taking. This should only be increased to achieve control of symptoms.
Go to www.mhra.gov.uk, click on ‘Safety information’ then ‘Safety warnings, alerts and recalls’. Scroll to 18 April, ‘Desmopressin nasal spray: removal of the primary nocturnal enuresis (bedwetting) indication’.